Lonza Group (FRA:LO3) Piotroski F-Score: 7 (As of Jun. 27, 2026) — Near Median


FRA:LO3 Lonza Group Ltd FRA:LO3
73 GF Score
Price €579.60
GF Value €641.26
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Lonza Group Piotroski F-Score?

Lonza Group FRA:LO3 -0.07% 73 Piotroski F-Score is 7 as of Jun. 27, 2026, which is at its 10-year median of 7.00. GuruFocus rates FRA:LO3 with a GF Score™ of 73/100 and a GF Value™ of €641.26 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, Lonza Group ranks better than 93.84% on this metric.

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Lonza Group has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Lonza Group's Piotroski F-Score or its related term are showing as below:

FRA:LO3' s Piotroski F-Score Range Over the Past 10 Years
Min: 5   Med: 7   Max: 7
Current: 7

During the past 13 years, the highest Piotroski F-Score of Lonza Group was 7. The lowest was 5. And the median was 7.

Lonza Group  (FRA:LO3) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Lonza Group Piotroski F-Score Related Terms


Lonza Group Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Lonza Group's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lonza Group Piotroski F-Score Chart

Lonza Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 6.00 5.00 6.00 7.00

Lonza Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 0.00 6.00 0.00 7.00

FRA:LO3 vs TMO, DHR, IDXX: Piotroski F-Score Comparison

For the Diagnostics & Research subindustry, Lonza Group's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lonza Group Piotroski F-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Lonza Group's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Lonza Group's Piotroski F-Score falls into.


FRA:LO3
73GF Score
Lonza Group Ltd FRA:LO3
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was €-295 Mil.
Cash Flow from Operations was €1,239 Mil.
Revenue was €6,999 Mil.
Gross Profit was €2,474 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was (21136.177 + 19190.084) / 2 = €20163.1305 Mil.
Total Assets at the begining of this year (Dec24) was €21,136 Mil.
Long-Term Debt & Capital Lease Obligation was €4,498 Mil.
Total Current Assets was €7,324 Mil.
Total Current Liabilities was €3,885 Mil.
Net Income was €681 Mil.

Revenue was €5,870 Mil.
Gross Profit was €1,920 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was (17864.958 + 21136.177) / 2 = €19500.5675 Mil.
Total Assets at the begining of last year (Dec23) was €17,865 Mil.
Long-Term Debt & Capital Lease Obligation was €4,936 Mil.
Total Current Assets was €5,827 Mil.
Total Current Liabilities was €3,833 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Lonza Group's current Net Income (TTM) was -295. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Lonza Group's current Cash Flow from Operations (TTM) was 1,239. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=-294.704/21136.177
=-0.01394311

ROA (Last Year)=Net Income/Total Assets (Dec23)
=681.225/17864.958
=0.03813191

Lonza Group's return on assets of this year was -0.01394311. Lonza Group's return on assets of last year was 0.03813191. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Lonza Group's current Net Income (TTM) was -295. Lonza Group's current Cash Flow from Operations (TTM) was 1,239. ==> 1,239 > -295 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=4497.726/20163.1305
=0.22306685

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=4935.666/19500.5675
=0.25310371

Lonza Group's gearing of this year was 0.22306685. Lonza Group's gearing of last year was 0.25310371. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=7323.674/3884.741
=1.88524126

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=5826.828/3833.496
=1.51997759

Lonza Group's current ratio of this year was 1.88524126. Lonza Group's current ratio of last year was 1.51997759. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Lonza Group's number of shares in issue this year was 70.235. Lonza Group's number of shares in issue last year was 71.293. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2474.446/6998.963
=0.35354466

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1920.497/5869.672
=0.32718983

Lonza Group's gross margin of this year was 0.35354466. Lonza Group's gross margin of last year was 0.32718983. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=6998.963/21136.177
=0.33113666

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=5869.672/17864.958
=0.32855784

Lonza Group's asset turnover of this year was 0.33113666. Lonza Group's asset turnover of last year was 0.32855784. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+0+1+1+1+1+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Lonza Group has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 7 mean?
Lonza Group (FRA:LO3) has a Piotroski F-Score of 7 as of Jun. 27, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Lonza Group and its competitors. This is near median its historical median of 7.00. Over the past decade, Lonza Group's Piotroski F-Score has ranged from 5.00 to 7.00. According to the industry distribution chart, Lonza Group ranks #13 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 6.2%.
Is Lonza Group's Piotroski F-Score too high?
Lonza Group's current Piotroski F-Score of 7 is near median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 7.00. The Medical Diagnostics & Research industry median Piotroski F-Score is 5.00. Lonza Group's value of 7 is 40% above this industry median. Based on the distribution chart, Lonza Group ranks #13 out of 211 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Lonza Group has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lonza Group's Piotroski F-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Lonza Group ranks #13 out of 211 companies for Piotroski F-Score. This places Lonza Group in the top 6% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Lonza Group's value of 7 is 40% above this benchmark. Historically, Lonza Group's own Piotroski F-Score has ranged from 5.00 to 7.00 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 5.00, Lonza Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Diagnostics & Research company?
The median Piotroski F-Score among Medical Diagnostics & Research companies is 5.00, based on 211 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lonza Group's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Lonza Group and its competitors. For the Medical Diagnostics & Research industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lonza Group's current Piotroski F-Score is 7, which is near median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lonza Group stock overvalued right now?
Based on GuruFocus' analysis, Lonza Group (FRA:LO3) is currently considered Modestly Undervalued. The stock's GF Value™ is €641.26, compared to a current price of €579.60 — trading 9.6% below its estimated fair value. The current Piotroski F-Score is 7, which is near median its 10-year median of 7.00 and 40% above the Medical Diagnostics & Research industry median of 5.00. Lonza Group's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Lonza Group (FRA:LO3), the current Piotroski F-Score is 7 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lonza Group (FRA:LO3) Overvalued in 2026?

Based on GuruFocus' analysis, Lonza Group stock appears to be undervalued. The current stock price of €579.60 is trading 9.6% below its estimated GF Value™ of €641.26. GuruFocus considers Lonza Group to be Modestly Undervalued.

Key valuation signals for FRA:LO3:

  • Piotroski F-Score: 7 (near median its 10-year median of 7.00)
  • GF Value™: €641.26 vs. price of €579.60 (9.6% below fair value)
  • GF Score™: 73/100 with 2 warning signs
  • Industry Position: 40% above the Medical Diagnostics & Research median (#13 of 211)

No single metric tells the full story. See the FRA:LO3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lonza Group Business Description

Address Muenchensteinerstrasse 38, Basel, CHE, 4002
Lonza Group is a contract development and manufacturing organization. It operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
73GF Score

Get the complete analysis for FRA:LO3

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€579.60
Price
€641.26
GF Value